899 related articles for article (PubMed ID: 26608188)
21. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A; Castro-Poceiro J; Panés J
Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
[TBL] [Abstract][Full Text] [Related]
22. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
23. Targeting JAK-STAT signal transduction in IBD.
Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
26. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Kim JW; Kim SY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768752
[TBL] [Abstract][Full Text] [Related]
27. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
Tavakolpour S
Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
[TBL] [Abstract][Full Text] [Related]
29. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
30. Emerging Therapies for Inflammatory Bowel Disease.
Weisshof R; El Jurdi K; Zmeter N; Rubin DT
Adv Ther; 2018 Nov; 35(11):1746-1762. PubMed ID: 30374806
[TBL] [Abstract][Full Text] [Related]
31. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
33. Innovations in Oral Therapies for Inflammatory Bowel Disease.
Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
36. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
38. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Danese S; Argollo M; Le Berre C; Peyrin-Biroulet L
Gut; 2019 Oct; 68(10):1893-1899. PubMed ID: 31227590
[TBL] [Abstract][Full Text] [Related]
39. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
40. Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes.
Galien R
Pharmacol Rep; 2016 Aug; 68(4):789-96. PubMed ID: 27162106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]